A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches

• Published in: Vaccine 2024-02, Vol.42 (6), p.1230-1246
• Main Authors: Soble, Adam, Ko, Melissa, Gilchrist, Shawn, Malvolti, Stefano, Hasso-Agopsowicz, Mateusz, Giersing, Birgitte, Amorij, Jean-Pierre, Jarrahian, Courtney, El Sheikh, Fayad, Menozzi-Arnaud, Marion, Scarna, Tiziana
• Format: Article
• Language: English
• Subjects: Clinical trials; Cold storage; Conjugates; Coronaviruses; Coverage and equity; COVID-19 vaccines; Disease; Epidemics; Humans; Immunization; Infant; Innovations; Low- and middle-income countries; Measles; Measles - prevention & control; Measles-Mumps-Rubella Vaccine; microarray technology; Mumps; Mumps - prevention & control; Mumps Vaccine; Pandemics; Product development; Public health; Rubella; Rubella - prevention & control; Rubella Vaccine; Technological change; Tetanus; Typhoid; typhoid fever; Typhoid Fever - prevention & control; Typhoid-Paratyphoid Vaccines; Use-cases; Vaccination; Vaccine microarray patches; Vaccine policy; Vaccine product innovation; Vaccines; Vaccines, Conjugate; Whooping cough
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2023.12.047

•Vaccine microarray patches have the potential for broad utility across various health and non-health settings, may extend the cadre of individuals capable of administering vaccines, and could enable new vaccine delivery channels.•Use cases help define priority target populations that can be reached with a new vaccine presentation most effectively and highlight the most relevant delivery strategies and their implications on health systems.•The potential for broad use of vaccine microarray patches suggests a sizeable market for these new products.•The use cases for vaccine microarray patches highlight critical product attributes that enable the novel vaccine presentation to provide public health value, which can help optimize clinical development and inform target product profiles.•Broad adoption of vaccine microarray patches will require supportive vaccine policy changes to enable the administration of vaccines by new cadres of health-workers and to improve access to vaccines in hard-to-reach communities. As an innovative vaccine delivery technology, vaccine microarray patches could have a meaningful impact on routine immunization coverage in low- and middle-income countries, and vaccine deployment during epidemics and pandemics. This review of the potential use cases for a subset of vaccine microarray patches in various stages of clinical development, including measles-rubella, measles-mumps-rubella, and typhoid conjugate, highlights the breadth of their applicability to support immunization service delivery and their potential scope of utilization within national immunization programs. Definition and assessment of the use cases for this novel vaccine presentation provide important insights for vaccine developers and policymakers into the strengths of the public health and commercial value propositions, and the preparatory requirements for public health systems for the future rollout of vaccine microarray patches. An in-depth understanding of use cases for vaccine microarray patches serves as a foundational input to overcoming the remaining technical, regulatory, and financial challenges. Additional efforts will help to realize the potential of vaccine microarray patches as part of the global effort to improve the coverage and equity of national immunization programs.